Recent research suggests that a routine blood test may have the ability to predict the likelihood of developing preeclampsia in pregnant individuals during labor. The American Society of Anesthesiologists (ASA) presented their findings at the Anesthesiology 2024 annual meeting, indicating that by measuring the ratio of blood proteins fibrinogen and albumin during routine blood tests upon arrival at the hospital, doctors can predict the risk of postpartum preeclampsia. Fibrinogen is involved in blood clotting and inflammation, while albumin helps maintain fluid balance and carries essential components throughout the body. Disruption of these proteins is associated with preeclampsia, and a higher fibrinogen-to-albumin ratio is linked to increased inflammation, infection, and other health conditions, indicating a greater risk for preeclampsia.
Understanding Preeclampsia
Preeclampsia is a serious pregnancy complication characterized by high blood pressure and organ damage, typically occurring after the 20th week of pregnancy. If left untreated, it can lead to complications like seizures, organ damage, and even death, posing risks to both the birthing parent and the baby. Early detection and proper management are crucial to minimizing these risks.
The research findings are yet to be peer-reviewed and published in a medical journal, but plans are in place to do so. Dr. Katz, the lead researcher, highlights the potential of this blood test marker in predicting and managing preeclampsia, ultimately improving maternal healthcare and decision-making processes during labor.
